SUPPLY AND PURCHASE AGREEMENTSupply and Purchase Agreement • May 10th, 2005 • Gen Probe Inc • Services-commercial physical & biological research • California
preliminary and subject to modification. Manufacturing may be performed with generic batch record where redlining of manufacturing documents by the operator are acceptable. Neither official Quality Control testing by ROCHE nor Quality Assurance release by ROCHE will be required for Draft Production Lots. Certificate of Analysis indicating purity and identity is required.
AMENDMENT NO. 6 TO AGREEMENTAmendment No. 6 to Agreement • May 10th, 2005 • Gen Probe Inc • Services-commercial physical & biological research
This Amendment No. 6 (“Amendment No. 6”) effective as of January 1, 2004 (the “Amendment Effective Date”) to that certain Agreement between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) and Chiron Corporation, a Delaware corporation (“Chiron”) dated as of June 11, 1998, as amended from time to time as of the Amendment Effective Date (the “Agreement”).
Gen-Probe Incorporated Amendment to Deferred Issuance Restricted Stock Conversion Agreement and Deferred Issuance Restricted Stock Election Agreement (The 2003 Incentive Award Plan)Deferred Issuance Restricted Stock Conversion Agreement and Deferred Issuance Restricted Stock Election Agreement • May 10th, 2005 • Gen Probe Inc • Services-commercial physical & biological research • California
This Amendment (the “Amendment”) to the Deferred Issuance Restricted Stock Conversion Agreement (“Conversion Agreement”) and Deferred Issuance Stock Election Agreement (the “Election Agreement”) entered into by and between Gen-Probe Incorporated (the “Company”) and Henry L. Nordhoff (“Employee”) is effective as of February 1, 2005.
MODIFIED BLOOD SCREENING INSTRUMENT - eSAS 2 ADDENDUM AMENDING AGREEMENT ENTERED INTO AS OF JUNE 11, 1998 BY AND BETWEEN GEN-PROBE INCORPORATED, A DELAWARE CORPORATION AND CHIRON CORPORATION effective as of January 1, 2002Modified Blood Screening Instrument - Esas 2 Addendum • May 10th, 2005 • Gen Probe Inc • Services-commercial physical & biological research
This Modified Blood Screening Instrument — eSAS 2 Addendum (“eSAS 2 Addendum”) is entered into, effective as of January 1, 2002 (“Addendum Effective Date”) pursuant to and amending that certain Agreement entered into as of June 11, 1998 (“Agreement”) by and between Gen-Probe Incorporated, a Delaware corporation (“Gen-Probe”) with a principal place of business at 10210 Genetic Center Drive, San Diego CA 92121, and Chiron Corporation, a Delaware corporation (“Chiron;” Chiron and Gen-Probe each is individually referred to as “Party” and collectively are referred to as the “Parties”) with a place of business at 4560 Horton Street, Emeryville, CA 94608.
